Innocan Pharma Stock Performance
| INNPF Stock | USD 5.76 0.16 2.70% |
The company retains a Market Volatility (i.e., Beta) of -1.12, which attests to a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning InnoCan Pharma are expected to decrease slowly. On the other hand, during market turmoil, InnoCan Pharma is expected to outperform it slightly. At this point, InnoCan Pharma has a negative expected return of -1.1%. Please make sure to check out InnoCan Pharma's value at risk, as well as the relationship between the rate of daily change and period momentum indicator , to decide if InnoCan Pharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days InnoCan Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in February 2026. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 2.3 M | |
| Total Cashflows From Investing Activities | -48 K |
InnoCan |
InnoCan Pharma Relative Risk vs. Return Landscape
If you would invest 1,234 in InnoCan Pharma on October 15, 2025 and sell it today you would lose (658.00) from holding InnoCan Pharma or give up 53.32% of portfolio value over 90 days. InnoCan Pharma is currently producing negative expected returns and takes up 4.9466% volatility of returns over 90 trading days. Put another way, 44% of traded otc stocks are less volatile than InnoCan, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
InnoCan Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for InnoCan Pharma's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as InnoCan Pharma, and traders can use it to determine the average amount a InnoCan Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2221
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | INNPF |
Based on monthly moving average InnoCan Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of InnoCan Pharma by adding InnoCan Pharma to a well-diversified portfolio.
InnoCan Pharma Fundamentals Growth
InnoCan OTC Stock prices reflect investors' perceptions of the future prospects and financial health of InnoCan Pharma, and InnoCan Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on InnoCan OTC Stock performance.
| Return On Equity | -0.59 | |||
| Return On Asset | -0.58 | |||
| Profit Margin | (2.17) % | |||
| Operating Margin | (4.95) % | |||
| Current Valuation | 47.63 M | |||
| Shares Outstanding | 249.62 M | |||
| Price To Book | 7.19 X | |||
| Price To Sales | 39.64 X | |||
| Revenue | 196 K | |||
| EBITDA | (10.04 M) | |||
| Cash And Equivalents | 7.73 M | |||
| Cash Per Share | 0.03 X | |||
| Total Debt | 12 K | |||
| Debt To Equity | 0 % | |||
| Book Value Per Share | 0.03 X | |||
| Cash Flow From Operations | (6.63 M) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 12.57 M | |||
About InnoCan Pharma Performance
By analyzing InnoCan Pharma's fundamental ratios, stakeholders can gain valuable insights into InnoCan Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if InnoCan Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if InnoCan Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
InnoCan Pharma Corporation, a pharmaceutical company, focuses on the development of various drug delivery platforms combining cannabidiol with other pharmaceutical ingredients in the United States, Poland, France, and internationally. InnoCan Pharma Corporation was incorporated in 2018 and is headquartered in Calgary, Canada. Innocan Pharma is traded on OTC Exchange in the United States.Things to note about InnoCan Pharma performance evaluation
Checking the ongoing alerts about InnoCan Pharma for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for InnoCan Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| InnoCan Pharma generated a negative expected return over the last 90 days | |
| InnoCan Pharma has high historical volatility and very poor performance | |
| InnoCan Pharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 196 K. Net Loss for the year was (10.05 M) with profit before overhead, payroll, taxes, and interest of 121 K. | |
| InnoCan Pharma has accumulated about 7.73 M in cash with (6.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.03. | |
| Roughly 28.0% of the company shares are held by company insiders |
- Analyzing InnoCan Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether InnoCan Pharma's stock is overvalued or undervalued compared to its peers.
- Examining InnoCan Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating InnoCan Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of InnoCan Pharma's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of InnoCan Pharma's otc stock. These opinions can provide insight into InnoCan Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for InnoCan OTC Stock analysis
When running InnoCan Pharma's price analysis, check to measure InnoCan Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy InnoCan Pharma is operating at the current time. Most of InnoCan Pharma's value examination focuses on studying past and present price action to predict the probability of InnoCan Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move InnoCan Pharma's price. Additionally, you may evaluate how the addition of InnoCan Pharma to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |